| 2018 | 2017 | 2016 | 2015 | 2014 |
Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™
November 14, 2016
Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 09, 2016
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
November 09, 2016
Ocular Therapeutix™ to Hold Third Quarter 2016 Financial Results Conference Call on Wednesday, November 9, 2016
November 02, 2016
Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer
October 20, 2016
Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases
October 13, 2016
Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
October 13, 2016
Ocular Therapeutix™ Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension
October 04, 2016
Ocular Therapeutix™ to Participate in the Morgan Stanley Global Healthcare Conference
August 31, 2016
Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 09, 2016
Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)
August 05, 2016
Ocular Therapeutix™ Provides Update on NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
August 03, 2016
Ocular Therapeutix™ to Report Second Quarter 2016 Financial Results
August 02, 2016
Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
July 25, 2016
Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
July 06, 2016
Ocular Therapeutix™ Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA™ for the Treatment of Allergic Conjunctivitis
June 06, 2016
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
June 02, 2016
Ocular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016
Ocular Therapeutix™ to Report First Quarter 2016 Financial Results
May 03, 2016
Ocular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension
April 27, 2016
Ocular Therapeutix™ to Host Investor Day on April 6, 2016
March 28, 2016
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2015 Financial Results
March 10, 2016
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2015 Financial Results
March 02, 2016
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
February 18, 2016
Ocular Therapeutix™ Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension
February 16, 2016
Ocular Therapeutix™ Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer
January 11, 2016
